翰宇药业
(300199)
| 流通市值：186.66亿 | | | 总市值：221.25亿 |
| 流通股本：7.45亿 | | | 总股本：8.83亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 299,145,924.16 | 966,352,079.7 | 683,122,870.45 | 549,442,106.79 |
| 营业收入 | 299,145,924.16 | 966,352,079.7 | 683,122,870.45 | 549,442,106.79 |
| 二、营业总成本 | 209,222,759.88 | 886,483,321.15 | 607,896,350.24 | 407,008,743.17 |
| 营业成本 | 105,014,681.94 | 402,355,317.17 | 274,305,994.42 | 206,243,861.32 |
| 税金及附加 | 2,480,057.47 | 13,603,928.58 | 7,774,443.65 | 5,438,755.44 |
| 销售费用 | 11,744,975.32 | 106,964,190.05 | 78,746,339.16 | 38,968,390.15 |
| 管理费用 | 32,939,848.21 | 123,977,508.28 | 88,404,681.45 | 57,456,563.57 |
| 研发费用 | 30,873,123.71 | 126,850,998.85 | 74,125,204.88 | 46,839,900.41 |
| 财务费用 | 26,170,073.23 | 112,731,378.22 | 84,539,686.68 | 52,061,272.28 |
| 其中:利息费用 | 23,279,327.05 | 98,036,096.84 | 73,080,287.57 | 50,514,918.51 |
| 其中:利息收入 | 224,454.36 | 559,476.03 | 412,611.29 | 198,205.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -54,265.57 | 153,724.57 | 154,094.29 | 215,783.62 |
| 加:投资收益 | 46,983,251.42 | 1,346,384.37 | 2,723,249.93 | 936,950.62 |
| 资产处置收益 | 1,646,373.17 | 617,186.97 | 623,413.38 | 552,485.01 |
| 资产减值损失(新) | -1,704,917.78 | -31,252,039.51 | -9,043,143.95 | -1,411,875.22 |
| 信用减值损失(新) | -3,160,515.01 | -7,571,263.99 | -171,916.43 | -2,274,368.27 |
| 其他收益 | 3,693,991.25 | 25,931,952.31 | 22,760,237.98 | 19,587,713.95 |
| 四、营业利润 | 137,327,081.76 | 69,094,703.27 | 92,272,455.41 | 160,040,053.33 |
| 加:营业外收入 | 114,585.32 | 554,060.61 | 296,222 | 48,925.06 |
| 减:营业外支出 | 549,322.99 | 5,418,871.05 | 4,955,004 | 128,125.32 |
| 五、利润总额 | 136,892,344.09 | 64,229,892.83 | 87,613,673.41 | 159,960,853.07 |
| 减:所得税费用 | 9,497,520.99 | 30,203,882.06 | 17,855,599.94 | 15,441,496.15 |
| 六、净利润 | 127,394,823.1 | 34,026,010.77 | 69,758,073.47 | 144,519,356.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 127,394,823.1 | 34,026,010.77 | 69,758,073.47 | 144,519,356.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 127,814,053.73 | 36,569,897.15 | 71,351,483.5 | 145,468,616.41 |
| 少数股东损益 | -419,230.63 | -2,543,886.38 | -1,593,410.03 | -949,259.49 |
| 扣除非经常损益后的净利润 | 123,830,589.47 | 13,806,615.48 | 50,829,428.52 | 123,380,468.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.04 | 0.08 | 0.16 |
| (二)稀释每股收益 | 0.14 | 0.04 | 0.08 | 0.16 |
| 八、其他综合收益 | -267,945.47 | -1,258,380.34 | -841,191.83 | -323,282.97 |
| 归属于母公司股东的其他综合收益 | -267,945.47 | -1,258,380.34 | -841,191.83 | -323,282.97 |
| 九、综合收益总额 | 127,126,877.63 | 32,767,630.43 | 68,916,881.64 | 144,196,073.95 |
| 归属于母公司股东的综合收益总额 | 127,546,108.26 | 35,311,516.81 | 70,510,291.67 | 145,145,333.44 |
| 归属于少数股东的综合收益总额 | -419,230.63 | -2,543,886.38 | -1,593,410.03 | -949,259.49 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |